What does “Clear” mean?
The animal does not carry the mutation. It will not develop the disease and will not pass it on.
The Centronuclear Myopathy In Labrador Variant 2 (CNM) DNA test is essential for responsible Labrador owners and breeders. This genetic test detects the presence of the CNM mutation, a hereditary muscle disorder affecting Labradors. Early identification through DNA testing helps prevent the breeding of affected dogs, promoting healthier litters. CNM causes muscle weakness and mobility issues, impacting a dog’s quality of life. By using the CNM DNA test, breeders can make informed decisions to reduce the incidence of this condition. Regular testing supports the overall health and longevity of Labrador Retrievers. Ensure your Labrador’s well-being with accurate CNM genetic screening today.
The Centronuclear Myopathy In Labrador Variant 2 (CNM) DNA test detects a genetic mutation responsible for a muscle disorder in Labrador Retrievers. This condition causes muscle weakness and difficulty with movement, often appearing in young dogs. Early identification through testing helps breeders avoid passing the mutation to offspring. Responsible breeding practices reduce the incidence of CNM and improve the overall health of the breed. DNA testing is a valuable tool for maintaining the well-being of Labradors.
This DNA test is included starting from our pack Basic — and is also part of the packs Basic, Standard, Advanced, Complete.
View DNA Test Packs →Centronuclear Myopathy in Labrador Variant 2 (CNM) is a genetic condition that primarily affects the muscle function in dogs, particularly in the Labrador Retriever breed. This myopathy is characterized by the presence of abnormal muscle fibers, which lead to muscle weakness and reduced mobility. The condition is caused by mutations in specific genes that are crucial for muscle development and maintenance.
The clinical signs of CNM typically appear in young dogs, often manifesting between six months and two years of age. Affected dogs may exhibit symptoms such as muscle weakness, difficulty in rising, exercise intolerance, and a tendency to become easily fatigued. Additionally, they may have a characteristic dropped posture due to weakness in the muscles of the hind limbs. The severity of symptoms can vary significantly among affected individuals.
At the cellular level, CNM is associated with abnormalities in the structure and function of muscle cells. The condition leads to the accumulation of centronuclear myopathy, where the nuclei of muscle fibers are located in the center rather than at the periphery. This abnormal positioning can impair normal muscle function and regeneration, ultimately resulting in progressive muscle weakness over time.
Diagnosing Centronuclear Myopathy involves a combination of clinical evaluation and genetic testing. Veterinarians typically assess the dog’s medical history and perform a thorough physical examination. Muscle biopsies may also be conducted to observe the characteristic changes in muscle fibers. However, the definitive diagnosis is made through genetic testing that identifies the specific mutations associated with CNM.
Currently, there is no cure for Centronuclear Myopathy, and treatment options are primarily focused on managing symptoms and improving the quality of life for affected dogs. Supportive care, including physical therapy and weight management, can help maintain muscle function and mobility. Additionally, regular veterinary check-ups are essential for monitoring the condition and addressing any complications that may arise.
Genetic testing plays a vital role in the management of CNM, particularly for breeding decisions. By identifying carriers of the CNM mutation, breeders can make informed choices to reduce the risk of producing affected offspring. This proactive approach is crucial for controlling the prevalence of this condition in the population and promoting the overall health of the breed.
Centronuclear Myopathy in Labrador Variant 2 is a significant genetic disorder that impacts muscle function in dogs. Understanding the condition, its symptoms, and the importance of genetic testing can aid in better management and care for affected animals. Ongoing research and advancements in veterinary genetics continue to enhance our understanding of CNM, paving the way for potential future therapies and improved outcomes for affected dogs.
The animal does not carry the mutation. It will not develop the disease and will not pass it on.
No. The animal is generally healthy but can transmit the mutation to its offspring.
It carries two mutated copies. Clinical signs are expected depending on the disease. It should not be bred.
Some diseases are sex-linked, so their expression varies depending on the animal’s sex.
This DNA test detects the mutation associated with Centronuclear Myopathy In Labrador Variant 2 (CNM-L2) in order to identify clear, carrier, or at-risk animals.
DNA testing helps breeders plan safer matings and reduce the risk of transmitting the mutation to offspring.
The inheritance mode reported for this test is Autosomal Recessive.
This test analyses the mutation HACD1 insCACACAAAGGTTT].
Not necessarily. Interpretation depends on the inheritance pattern and the resulting genotype.
Pelé Manuel, Tiret Laurent, Kessler JeanLouis, Blot Stéphane, Panthier JeanJacques. SINE exonic insertion in the PTPLA gene leads to multiple splicing defects and segregates with the autosomal recessive centronuclear myopathy in dogs. Hum Mol Genet. 2005 Jun 1;14(11):1417-27. doi: 10.1093/hmg/ddi151. Epub 2005 Apr 13.
Your privacy, your choice
We use essential cookies to run the website. Optional cookies (such as embedded content providers) are disabled by default and are only enabled if you agree. You can change your choice anytime using the “Cookies” button.
Required for core features and security. Always enabled.
Improves features like preference saving or non-advertising embeds.
Helps us understand site usage. Disabled by default.
Advertising/tracking across sites (some video/maps embeds). Disabled by default.